Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| rs-ness | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a non-interventional clinical trial analyzing EEG recordings from people with epilepsy. Participants wear a comfortable EEG headband at home for several weeks. The goal is to study changes in brain activity that occur before seizures (called "pre-ictal patterns") and to test whether a software algorithm can predict seizures in real-time based on these patterns. No treatments or medications are being tested. The study will help evaluate whether seizure prediction is possible using wearable EEG devices and can support the development of future tools that give patients early warnings before seizures occur.
This observational study aims to evaluate the feasibility of real-time seizure prediction using non-invasive, wearable EEG devices in patients with epilepsy. The study focuses on identifying pre-ictal EEG patterns-subtle changes in brain activity that occur prior to seizure onset-and validating a prediction algorithm based on these patterns.
Epileptic seizures often occur unpredictably, significantly affecting patients' quality of life and safety. Existing seizure detection systems operate only after seizure onset. In contrast, predicting seizures before they occur could enable timely interventions, increase patient autonomy, and reduce the risks associated with uncontrolled seizures.
The study involves home use of consumer-grade wearable EEG devices (e.g., BrainBit and Muse headbands), which transmit EEG data via Bluetooth to a mobile app developed by the sponsor. Participants are instructed to wear the device daily for at least 12 weeks. The mobile app provides feedback on signal quality and securely uploads the data to the cloud for analysis. Participants can record seizures through the app, and researchers will also collect medical records for additional clinical annotations when available.
The prediction algorithm being tested uses personalized calibration and advanced statistical control of false alarm rates to ensure clinical viability. The algorithm was initially developed and tested using retrospective hospital-grade EEG data and publicly available datasets. This trial extends that work into the real world, evaluating the algorithm's performance prospectively on wearable data.
Key aims include:
Evaluating the usability of wearable EEG devices for long-term home use in a diverse patient population.
Identifying consistent pre-ictal EEG features within and across patients.
Validating the performance of the seizure prediction algorithm in terms of sensitivity, specificity, and false alarm rate.
Exploring the consistency of pre-ictal patterns across multiple seizures for the same patient.
This feasibility trial is non-interventional and does not alter participants' treatment plans. All data are collected passively and analyzed after being de-identified. Ethics approvals were obtained. The study is expected to contribute critical evidence toward the development of a clinically useful, AI-powered seizure forecasting system for real-world use.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Wearable EEG headband for passive brain signal acquisition | Device | This intervention involves the use of non-invasive, consumer-grade wearable EEG headbands to passively record brain activity from individuals with epilepsy in their natural home environments. The devices include BrainBit Headband, BrainBit Mindo, BrainBit Headphones, Muse 2, and Muse S. These devices transmit EEG signals via Bluetooth to a mobile application developed by the sponsor. The app provides real-time feedback on signal quality and securely uploads data to the cloud for offline analysis. The wearable devices are used solely for passive data acquisition and are not being evaluated for safety or therapeutic effectiveness in this study. No changes are made to clinical care or treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Seizure prediction sensitivity | Proportion of EEG-labeled seizures correctly predicted by the algorithm within the predefined pre-ictal window. | At the end of the 12-week monitoring period |
| Seizure prediction specificity | Proportion of time without seizures correctly classified as non-seizure periods by the algorithm. | At the end of the 12-week monitoring period |
| Seizure prediction false alarm rate | Number of false alarms issued by the algorithm 48 hour of EEG monitoring | At the end of the 12-week monitoring period |
| Measure | Description | Time Frame |
|---|---|---|
| System uptime for real-time seizure prediction | Fraction of monitoring time during which the system successfully issues predictions, reflecting adequate EEG signal quality and stable data flow. | Throughout the 12-week study period |
| Time Between Algorithm-Predicted Warning and Seizure Onset |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This study will enroll up to 150 individuals aged 12 years and older with a confirmed diagnosis of epilepsy, who experience between one seizure per day and two seizures over the past three months. Participants must be capable of using a wearable EEG device at home and have access to a compatible smartphone. Recruitment will occur at a tertiary hospital and affiliated community clinics in Israel to ensure diversity in epilepsy severity and demographics. The population includes both adults and adolescents, with safeguards for minors and cognitively impaired participants.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rambam Medical Center | Recruiting | Haifa | Israel |
Not provided
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
The latency between the algorithm's seizure prediction alarm and the actual clinical seizure onset. |
| Throughout the 12-week study period |
| Variability in Prediction Latency Across Events | The standard deviation of the latency between prediction alarm and seizure onset across all predicted seizures | Throughout the 12-week study period |
| Wearable EEG device battery and data usage | Quantitative analysis of daily battery consumption and mobile data usage during operation of the wearable EEG and Laura app. | Throughout the 12-week study period |
| Participant Adherence to Device Usage, Measured by Daily Wear Time | Mean number of hours per day the wearable EEG device is actively worn and recording, based on device logs. Adherence will be calculated as the percentage of study days in which participants wore the device for at least 8 hours. | Throughout the 12-week study period |
| Usability of the wearable EEG system | Participant-reported feedback on device comfort, ease of use, and satisfaction, measured through structured usability questionnaires at baseline, mid-study, and end of study. | Week 0, Week 6, and Week 12 |
| Frequency of Device-Related Skin Reactions | Number of device-related skin irritation events (e.g., redness, rash, pressure marks) reported by participants or observed by study staff, as recorded in a standardized adverse event log. | Throughout the 12-week study period |
| Severity of Device-Related Skin Reactions (Graded by CTCAE v5.0) | Maximum severity grade of each reported skin reaction during the study, based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death); only Grades 1-3 are expected. | Throughout the 12-week study period |
| Sheba Medical Center | Not yet recruiting | Ramat Gan | Israel |
|